Diversity in the Circulation of Influenza A(H3N2) Viruses in the Northern Hemisphere in the 2018-19 Season.
circulation
clade
influenza A
vaccine
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
13 Apr 2021
13 Apr 2021
Historique:
received:
23
01
2021
revised:
22
03
2021
accepted:
26
03
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
While vaccination is considered the most effective means to prevent influenza infection, its seasonal effectiveness varies, depending on the circulating influenza strains. Here, we characterized the circulation of influenza strains in October-2018 and March-2019 around the world. For this, we used nasopharyngeal samples collected from outpatient and hospitalized patients in Israel and data reported in ECDC, CDC, and WHO databases. Influenza A(H3N2) was dominant in Israel, while in Europe, Asia, and USA, A(H1N1)pdm09 virus circulated first, and then the A(H3N2) virus also appeared. Phylogenetic analysis indicated that A(H3N2) viruses circulating in Israel belonged to clade-3C.3a, while in Europe, Asia, and USA, A(H3N2) viruses belonged to subclade-3C.2a1, but were later replaced by clade-3C.3a viruses in USA. The vaccine A(H3N2) components of that year, A/Singapore/INFIMH-16-0019/2016-(H3N2)-like-viruses, belonged to clade-3C.2a1. The circulation of different influenza subtypes and clades of A(H3N2) viruses in a single season highlights the need for universal influenza vaccines.
Identifiants
pubmed: 33924296
pii: vaccines9040375
doi: 10.3390/vaccines9040375
pmc: PMC8069444
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Am J Public Health. 2013 Mar;103(3):e43-51
pubmed: 23327249
Vaccine. 2008 Sep 12;26 Suppl 4:D31-4
pubmed: 19230156
MMWR Morb Mortal Wkly Rep. 2016 Jun 10;65(22):567-75
pubmed: 27281364
J Med Virol. 2017 Jul;89(7):1186-1191
pubmed: 28004402
BMC Evol Biol. 2007 Nov 08;7:214
pubmed: 17996036
Euro Surveill. 2019 Nov;24(48):
pubmed: 31796152
Vaccine. 2018 Mar 7;36(11):1326-1329
pubmed: 29429813
PLoS Pathog. 2017 Jan 31;13(1):e1006194
pubmed: 28141862
Euro Surveill. 2017 Dec;22(50):
pubmed: 29258649
Nat Rev Microbiol. 2018 Jan;16(1):60
pubmed: 29109554
J Infect Dis. 2013 Oct 15;208(8):1305-14
pubmed: 23863950
J Virol. 2013 Nov;87(22):12447-56
pubmed: 24027322
Science. 2004 Jul 16;305(5682):371-6
pubmed: 15218094
Mol Biol Evol. 2008 Jul;25(7):1253-6
pubmed: 18397919
Vaccine. 2003 May 1;21(16):1776-9
pubmed: 12686093
Influenza Other Respir Viruses. 2014 Jul;8(4):422-30
pubmed: 24698156
J Clin Virol. 2017 Mar;88:12-16
pubmed: 28088665
Nature. 2015 Jul 9;523(7559):217-20
pubmed: 26053121
J Infect Dis. 2020 Jan 1;221(1):8-15
pubmed: 31665373
Euro Surveill. 2019 Feb;24(9):
pubmed: 30862331
Elife. 2015 Jan 16;4:e05055
pubmed: 25594904
Vaccines (Basel). 2020 Feb 09;8(1):
pubmed: 32050460
Euro Surveill. 2017 Aug 31;22(35):
pubmed: 28877844
J Antimicrob Chemother. 1999 Nov;44 Suppl B:3-9
pubmed: 10877456